Due to its cytotoxic effect in lymphoid cells, dexamethasone is widely used in the treatment of Multiple Myeloma. However, only a subset of myeloma patients responds to high-dose dexamethasone. Despite the undeniable anti-myeloma benefits of dexamethasone, significant adverse effects have been reported. The anti-tumor effect of dexamethasone was re-evaluated according to the molecular heterogeneity of Multiple Myeloma.
Cell lines are widely used in laboratories for in vitro experiments, especially for investigating abnormal hallmarks in cancer cells and identifying therapeutic targets. To achieve a representation of intracancer heterogeneity, several laboratories, have established cell line collections.
Myelomax is a preclinical CRO specializing in Multiple Myeloma target candidate testing and evaluation services for pharmaceutical and biotech companies, and research organizations who are working to advance therapies for Multiple Myeloma.